IT202200007226A1 - COMPOSITION INCLUDING LIPOIC ACID, VITAMIN D AND GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS - Google Patents
COMPOSITION INCLUDING LIPOIC ACID, VITAMIN D AND GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS Download PDFInfo
- Publication number
- IT202200007226A1 IT202200007226A1 IT102022000007226A IT202200007226A IT202200007226A1 IT 202200007226 A1 IT202200007226 A1 IT 202200007226A1 IT 102022000007226 A IT102022000007226 A IT 102022000007226A IT 202200007226 A IT202200007226 A IT 202200007226A IT 202200007226 A1 IT202200007226 A1 IT 202200007226A1
- Authority
- IT
- Italy
- Prior art keywords
- glutathione
- vitamin
- composition including
- lipoic acid
- nutraceutical compositions
- Prior art date
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title 2
- 239000000203 mixture Substances 0.000 title 2
- AGBQKNBQESQNJD-ZETCQYMHSA-N (S)-lipoic acid Chemical compound OC(=O)CCCC[C@H]1CCSS1 AGBQKNBQESQNJD-ZETCQYMHSA-N 0.000 title 1
- 108010024636 Glutathione Proteins 0.000 title 1
- 229960003180 glutathione Drugs 0.000 title 1
- 235000019136 lipoic acid Nutrition 0.000 title 1
- 239000002417 nutraceutical Substances 0.000 title 1
- 235000021436 nutraceutical agent Nutrition 0.000 title 1
- 229960002663 thioctic acid Drugs 0.000 title 1
- 229940088594 vitamin Drugs 0.000 title 1
- 229930003231 vitamin Natural products 0.000 title 1
- 235000013343 vitamin Nutrition 0.000 title 1
- 239000011782 vitamin Substances 0.000 title 1
- 150000003722 vitamin derivatives Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102022000007226A IT202200007226A1 (en) | 2022-04-12 | 2022-04-12 | COMPOSITION INCLUDING LIPOIC ACID, VITAMIN D AND GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS |
| PCT/IB2023/053742 WO2023199241A1 (en) | 2022-04-12 | 2023-04-12 | Composition comprising lipoic acid, vitamin d and glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102022000007226A IT202200007226A1 (en) | 2022-04-12 | 2022-04-12 | COMPOSITION INCLUDING LIPOIC ACID, VITAMIN D AND GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT202200007226A1 true IT202200007226A1 (en) | 2023-10-12 |
Family
ID=82196361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102022000007226A IT202200007226A1 (en) | 2022-04-12 | 2022-04-12 | COMPOSITION INCLUDING LIPOIC ACID, VITAMIN D AND GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT202200007226A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6649195B1 (en) * | 2002-07-11 | 2003-11-18 | Vitacost.Com, Inc. | Eyesight enhanced maintenance composition |
| US20070116779A1 (en) * | 2005-11-23 | 2007-05-24 | Elizabeth Mazzio | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease |
| US20090110674A1 (en) * | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
| JP2010120916A (en) * | 2008-11-22 | 2010-06-03 | Rena Science:Kk | Agent for amelioration or treatment of mental disease and nervous system disease developing in relation to decrease in physiologically active monoamine in vivo |
| WO2020053754A1 (en) | 2018-09-10 | 2020-03-19 | Uriach Italia S.R.L. | Composition comprising lipoic acid and vitamin d for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies |
| WO2022016038A1 (en) * | 2020-07-17 | 2022-01-20 | Dt Ip Holdings I, Llc | Formulation bases comprising hyaluronic acid and formulations of same |
-
2022
- 2022-04-12 IT IT102022000007226A patent/IT202200007226A1/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6649195B1 (en) * | 2002-07-11 | 2003-11-18 | Vitacost.Com, Inc. | Eyesight enhanced maintenance composition |
| US20070116779A1 (en) * | 2005-11-23 | 2007-05-24 | Elizabeth Mazzio | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease |
| US20090110674A1 (en) * | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
| JP2010120916A (en) * | 2008-11-22 | 2010-06-03 | Rena Science:Kk | Agent for amelioration or treatment of mental disease and nervous system disease developing in relation to decrease in physiologically active monoamine in vivo |
| WO2020053754A1 (en) | 2018-09-10 | 2020-03-19 | Uriach Italia S.R.L. | Composition comprising lipoic acid and vitamin d for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies |
| WO2022016038A1 (en) * | 2020-07-17 | 2022-01-20 | Dt Ip Holdings I, Llc | Formulation bases comprising hyaluronic acid and formulations of same |
Non-Patent Citations (10)
| Title |
|---|
| CAS , no. 67-97-0 |
| DATABASE GNPD [online] MINTEL; 28 September 2021 (2021-09-28), ANONYMOUS: "Daily Immunity Natural Raspberry & Lemon Effervescent Tablets", XP055978781, retrieved from https://www.gnpd.com/sinatra/recordpage/9039816/ Database accession no. 9039816 * |
| GALLA RGRISHENTI PHARGHITA MSACCUMAN LFERRACFORI PUBERTI F: "Ovotransferrin Supplement improves the Iron absorption: An in vitro Gastro-Intestinal Model", BIOMEDICINES, vol. 9, no. 11, 2021, pages 1543, XP055927367, DOI: 10.3390/biomedicines9111543 |
| HOFFMANN PBURMESTER MLANGEHEINE MBREHM RINDO MTCIRCLIP B ET AL.: "Caco-2/HT29-MTX co-cultured cells as a model for studying physiological properties and toxin-induced effects on intestinal cells", PLOS ONE, vol. 16, no. 10, 2021, pages e0257824 |
| HOFFMANN PBURMESTER MLANGEHEINE MBREHM RINDO MTCIRCLIP B ET AL.: "Caco-2/HT29-MTX co-cultured cells as a model for studying physiological properties and toxin-induced effects on intestines! cells", PLOS ONE, vol. 16, no. 10, 2021, pages e0257824 |
| HOFFMANN PBURMESTER MLANGEHEINE MBREHM RSEEGER B ET AL.: "Caco-2/HT29-MTXco-culturesas a model for studying physiological properties and toxin-induced effects on the intestines! cells", PLOS ONE, vol. 16, no. 10, 2021, pages e0257824 |
| KANWAL SABEYSINGHE SSRISAISALUP MBOONSERM P: "Cytotoxic effects and Intracellular Localization of Bin Toxin from Lysinibacillus sphaericus in Human Liver Cancer Cell Line", TOXINS (BASEL, vol. 13, no. 4, 19 April 2021 (2021-04-19), pages 288 |
| MOLINARI CMORSANUTO VGHIRLANDA S ET AL.: "Role of combined Lipoic acid and Vitamin D3 on Astrobytes as a way to prevent Brain aging by induced oxidative stress and Iron accumulation", OXID MED CELI LONGEV, 28 February 2019 (2019-02-28), pages 2843121 |
| MOLINARI CMORSANUTO VRUGA S ET AL.: "The role of BDNF on aging-Modulation Markers", BRAIN SKIING, vol. 10, no. 5, 9 May 2020 (2020-05-09), pages 285 |
| SRINIVASAN BKOLLI ARESCH MBABACI HESHULER MLHICKMAN JJ: "TEER measurement techniques for in vitro barrier model systems", J LAB AUTOM, vol. 20, no. 2, April 2015 (2015-04-01), pages 107 - 26, XP055560328, DOI: 10.1177/2211068214561025 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA94942C2 (en) | Dpp iv inhibitor formulations | |
| IL247260B (en) | A pharmaceutical spray composition containing an analogue of vitamin D and a corticosteroid | |
| BRPI0817423A2 (en) | Processes for preparing a compound, for preparing a pharmaceutical formulation, and for preparing an intermediate of a compound, and, compound | |
| WO2008131114A3 (en) | Pharmaceutical formulations containing lipoic acid derivatives | |
| ECSP10010167A (en) | NEW OPHTHALMIC COMPOSITIONS | |
| AR060387A1 (en) | FOOD SUPPLEMENTS AND THEIR USES | |
| BR112012032816A2 (en) | controlled release pharmaceutical composition, and methods for reducing the dietary effect of a controlled release composition, reducing the amount of time required to achieve a stable state for metformin, to improve the bioavailability of a controlled release dosage form. matrix | |
| UA107474C2 (en) | CHROMENONE DERIVATIVES WITH ANTI-TUMOR ACTIVITY | |
| BR112012026596A2 (en) | A method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and compositions comprising them. | |
| ECSP078002A (en) | PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS | |
| BRPI0814189A2 (en) | DOUBLE FILM RIBONUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND ITS USES, METHOD FOR INHIBITING PHOSPHYDYLINOSITOL 4-KINASE EXPRESSION, VECTOR AND USE OF A COMPOUND THAT SELECTIVELY INHIBITS PHOSPHTIDYLINOSITOL-4 PHASE. | |
| MX369477B (en) | PHARMACEUTICAL FORMULATIONS OF STATINES AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION. | |
| WO2011082290A3 (en) | Formulations from natural products, turmeric, and aspirin | |
| BR112017001968A2 (en) | two-chamber packaging for a multi-dose oral liquid pharmaceutical composition | |
| UY30215A1 (en) | CHROMANOL DERIVATIVES REPLACED, PROCEDURES FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
| MX378687B (en) | FAT-SOLUBLE VITAMIN FORMULATION. | |
| BR112016010875A8 (en) | USEFUL COMPOSITION FOR FEMALE FERTILITY PROMOTION | |
| EA201200616A1 (en) | DERIVATIVES 2-OXO-1-PIRROLIDININILIMIDAZOTHIAADIA ASOL | |
| EP4161900A4 (en) | CANNABIDIOL ACID (CBDA) DERIVATIVES AND USES THEREOF | |
| BR112013016590A2 (en) | use of glutamine stabilizers | |
| EP4122483A4 (en) | ORAL PHARMACEUTICAL COMPOSITION | |
| EP4171537A4 (en) | TOPICAL VITAMIN C COMPOSITION | |
| IL304247A (en) | Spirocyclohexane derivatives, pharmaceutical compositions containing them and their uses as anti-apoptotic inhibitors | |
| WO2013032558A3 (en) | Products for anti-inflammation support | |
| IT202200007226A1 (en) | COMPOSITION INCLUDING LIPOIC ACID, VITAMIN D AND GLUTATHIONE, ITS USES, AND RELATED PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS |